Elicio Therapeutics (ELTX)
Develops AMP-enabled cancer immunotherapies centered on the ELI-002 mutant-KRAS program.
Something off on this page? Send us feedback.
Develops AMP-enabled cancer immunotherapies centered on ELI-002 for mutant-KRAS pancreatic and colorectal cancers. Its platform directs off-the-shelf immunotherapies to lymph nodes, alongside preclinical programs for mutant-BRAF and mutant-TP53 cancers.
Develops AMP-enabled cancer immunotherapies, with ELI-002 for mutant-KRAS pancreatic and colorectal cancers as the lead program. The Amphiphile platform is designed to carry payloads with albumin to lymph nodes, where it is intended to activate cancer-specific T-cell responses.
ELI-007 and ELI-008 are preclinical follow-on candidates targeting mutant-BRAF and mutant-TP53 cancers. Clinical development is concentrated in ELI-002, which is listed as a Phase 2 program.
The current ELTX security began Nasdaq trading after a 2023 reverse merger. Planned Phase 3 development and further AMP-platform work depend on financing and partnership support.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Jun 16, 2026 | Jones Trading | Downgrade | ||
| Mar 13, 2026 | H.C. Wainwright | Target | Target: — | Target: $17 |
| Mar 9, 2026 | C.L. King | Target | Target: — | Target: $17 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $23.5M · Total debt $14.1M · Total assets $31.3M · Shareholders' equity $7.9M
- Revenue
- $0
- Operating income
- −$10.4M
- Net income
- −$8.2M
No dividends on record.
| Institutions | 20.74% | 3.96M shares | |
|---|---|---|---|
| 67 holders · as of Jun 30, 2026 | |||
| Insiders | 52.77% | 10.06M shares | |
| 6 holders · as of Feb 3, 2026 | |||
| Strategic holders | 7.39% | 1.41M shares | |
| 1 holder · as of Jul 16, 2026 | |||
| Other | 19.10% | 3.64M shares | |
| remainder | |||
19.07M company shares as of Aug 30, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (26.28M in the company's Sep 23, 2026 report, 19.07M elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Yekaterina Chudnovsky1Insiderdirector, 10 percent owner | 50.65% | 9.66M | filed Mar 7, 2025 |
Moti Investments LLCStrategic | 7.39% | 1.41M | filed Jul 16, 2026 |
Knoll Capital Management, LLCInstitution | 6.36% | 1.21M | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 4.02% | 766,005 | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 3.00% | 572,151 | as of Jun 30, 2026 |
- Yekaterina Chudnovsky's transaction reports restate only vehicles that traded; the 2025 ownership statement (9.66M) is used instead.
Insider tradesForm 4
No open-market trades in the last 12 months.
- Revolution Medicines
RAS inhibitor program spanning adjuvant and metastatic pancreatic cancer
- Bristol-Myers Squibb
Approved KRAS G12C targeted therapy for previously treated colorectal cancer
- Amgen
Approved KRAS G12C therapy and first-line colorectal-cancer trial
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Elicio Therapeutics | $1.90 | +1.60% | $35.7M | — | — | — | — |
| Revolution Medicines | $190.92 | −1.01% | $41.00B | — | — | — | — |
| Bristol-Myers Squibb | $61.51 | −1.19% | $127.16B | 13.7 | 9.6 | 2.6 | +5.7% |
| Amgen | $406.78 | −0.84% | $221.41B | 25.5 | 17.3 | 5.8 | +9.7% |
| Median | 19.6 | 13.5 | 4.2 | +7.7% |